Mark A. Green - Concepedia

Author

Mark A. Green

Purdue University West Lafayette ORCID

Also Known As

Green, Mark, M Green, M. Green, Mark A Green, Mark A. Green, Mark Green, S Thomson

114

Publications

Citations

H-Index

100

Concepts

All Affiliations

Purdue University West Lafayette Indiana University – Purdue University Indianapolis Harvard University Medical University of South Carolina Duke Medical Center

About

Mark A. Green is an author at Purdue University West Lafayette specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	19	961
2	Health Sciences	6	6	270
3	Biochemistry	6	6	340
4	Engineering	3	3	299
5	Cell Biology	3	3	124

Mark A. Green

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10 Charles Butts, Keyue Ding, Lesley Seymour, Journal of Clinical Oncology	2009	421
Synthesis, Purification, and Tumor Cell Uptake of <sup>67</sup>Ga-Deferoxamine−Folate, a Potential Radiopharmaceutical for Tumor Imaging Susan Wang, Robert J. Lee, Carla J. Mathias, Bioconjugate Chemistry	1996	241
Design and Synthesis of [<sup>111</sup>In]DTPA−Folate for Use as a Tumor-Targeted Radiopharmaceutical Susan Wang, Jin Luo, Douglas A. Lantrip, Bioconjugate Chemistry EngineeringTumor BiologyMedicinal ChemistryTheranosticsRadiopharmaceutical Therapy	1997	202
Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. Noah C. Choi, James E. Herndon, Julian Rosenman, Journal of Clinical Oncology	1998	197
Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma Patrick J. Loehrer, Michael R. Jiroutek, Seena C. Aisner, Cancer	2001	186
Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non–Small-Cell Lung Cancer: CALGB 30105 Mark A. Socinski, A. William Blackstock, Jeffrey A. Bogart, Journal of Clinical Oncology	2008	177
Randomized Phase II Study of Carboplatin and Etoposide With or Without the<i>bcl-2</i>Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103 Charles M. Rudin, Ravi Salgia, Xiaofei Wang, Journal of Clinical Oncology	2008	162
Preoperative Exercise Vo2 Measurement for Lung Resection Candidates: Results of Cancer and Leukemia Group B Protocol 9238 Gregory Loewen, Dorothy Watson, Leslie J. Kohman, Journal of Thoracic Oncology Lung TransplantationInterventional PulmonologyAdvanced Lung DiseaseMedicineExercise Physiology	2007	157
Activity of Docetaxel in Platinum-Treated Non–Small-Cell Lung Cancer: Results of a Phase II Multicenter Trial David R. Gandara, Everett E. Vokes, Mark A. Green, Journal of Clinical Oncology	2000	134
Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107) Thierry Jahan, Lin Gu, Robert A. Kratzke, Lung Cancer Calgb 30107Malignant DiseaseMalignant MesotheliomaMedicinePathology	2011	74

Page 1